Molecular characterization of Portuguese patients with dilated cardiomyopathy

Alexandra Sousa1, Paulo Canedo2, Olga Azevedo3

  • 1Department of Medicine, Faculty of Medicine, University of Porto, Portugal; Cintesis - Center for Research in Health Technologies and Services, Portugal; Department of Cardiology, Santa Maria Maior Hospital, Portugal.

Insights

Genetic variants in dilated cardiomyopathy (DCM) were identified in 26% of Portuguese patients, highlighting the complex genetic landscape of this heart condition. Further family studies are needed to clarify variant pathogenicity and improve risk stratification.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Genetic Epidemiology

Background:

  • Dilated cardiomyopathy (DCM) is a heart muscle disease with significant heritability, often showing autosomal dominant inheritance.
  • Molecular diagnosis of DCM is crucial for genetic counseling and patient risk stratification.
  • Understanding the genetic basis of DCM is essential for developing targeted therapies.

Purpose of the Study:

  • To determine the frequency of genetic variants in dilated cardiomyopathy (DCM) within the Portuguese population.
  • To elucidate the molecular basis of DCM in a cohort of Portuguese patients.
  • To identify novel genetic variants associated with DCM.

Main Methods:

  • A multicenter study screened 107 unrelated DCM patients recruited between 2013 and 2014.
  • Genetic variants in 15 genes were analyzed using next-generation sequencing and Sanger sequencing.
  • PCR amplification followed by direct sequencing was employed for variant detection.

Main Results:

  • Thirty-one rare variants were identified in eight genes, including MYBPC3, TNNT2, and LMNA, in 28 patients (26%).
  • Of the identified variants, nine were novel, 11 were associated with hypertrophic cardiomyopathy, and four were likely pathogenic.
  • No significant differences in clinical or imaging characteristics were observed between patients with and without rare variants.

Conclusions:

  • The genetic landscape of DCM in Portugal is complex and diverse.
  • Molecular cascade screening within families is essential for accurate interpretation of variant pathogenicity.
  • Further research is needed to establish genotype-phenotype correlations and refine risk stratification for DCM patients.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
548
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
465
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
512
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
390
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
580
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
344